Abstract: A method and device for treating cholesterol disorders includes administering at least one treatment regime including two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels prior to treatment. Treatment according to the method results in decreased LDL levels in patients having abnormal LDL levels and increased HDL levels in patients having abnormal HDL levels. Each subsequent round of plasmapheresis is conducted weekly, but no more than twice per week.
Type:
Application
Filed:
March 12, 2012
Publication date:
September 12, 2013
Applicant:
GRIFOLS, S.A.
Inventors:
Victor GRIFOLS LUCAS, Victor Grifols Roura
Abstract: Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluded at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.
Abstract: The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.
Abstract: The device comprises a support in the form of a tray or the like, which is at the top and provided inside with first grooves for guiding first cards arranged parallel to each other, forming a single level for the cards and is characterized in that it has sets of grooves interposed between the first grooves, allowing a second level of cards to be placed at a level higher than the first cards.
Abstract: A device for the application of two components of fibrin adhesive at a treatment site comprising a support for syringes comprising two parallel cylindrical housings to receive corresponding syringes and a plunger connecting member, characterised in that the said syringe support comprises a passage for insertion of the said plunger connecting member, the said passage being located in the space defined between the cylindrical housings of the said syringe support, the said plunger connector having a zone with a suitable geometry to slide within the said passage and in that the transverse cross-section of the said passage of the syringe support has a maximum opening at the ends and a minimum opening in the central part.
Abstract: Device for emptying a bag containing a frozen blood-derived product, including: a cutting device; an extractor for the product, a hopper for receiving the product, a device for transporting the bag from a receiving area to the plasma extractor, this transporting device including a robotic arm with a gripper which, in turn, includes: two catching arms, each defining at least a distal end and a proximal end, and an actuator, in which the actuator controls a mechanism for modifying the distance separating the distal ends of the gripper arms to catch the bag by its lower surface
Abstract: A concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF is prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of up to 12 IU VWF:RCo/ml and a VWF/Factor VIII ratio of 0.4 or more; and nanofiltering that starting solution through a filter of pore size of 35 nanometers or smaller. The resulting VWF retains high molecular weight multimers.
Type:
Grant
Filed:
January 7, 2009
Date of Patent:
January 15, 2013
Assignee:
Grifols, S.A.
Inventors:
Pere Ristol Debart, Maria Mercedes Faro Tomas, Juan Ignacio Jorquera Nieto
Abstract: The present invention relates to mammalian cell culture media which comprise supernatant from some of the fractions of human plasma fractionation according to the Cohn method, more specifically, the supernatant of fractions I and II+III. When said supernatant is added as a culture medium supplement it provides various nutrients and factors for the effective maintenance and/or proliferation of the cultured mammalian cells. In addition, the present invention relates to the preparation process and use of said medium in the culture of mammalian cells.
Type:
Grant
Filed:
July 2, 2010
Date of Patent:
August 28, 2012
Assignee:
Grifols, S.A.
Inventors:
Juan Ignacio Jorquera Nieto, Montserrat Costa Rierola, José María Diez Cervantes
Abstract: A process for detoxifying the blood of a patient in need thereof involves: collecting albumin from human plasma and/or plasma fractions; diafiltration of a mixture containing the collected albumin; stabilizing the resulting diafiltered albumin mixture with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin mixture; diafiltering the pasteurized mixture to remove, among other things, stabilizers; and detoxifying the blood of the patient by administering the resulting albumin to the patient. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.
Type:
Grant
Filed:
February 15, 2011
Date of Patent:
July 31, 2012
Assignee:
Grifols, S.A.
Inventors:
Juan Ignacio Jorquera Nieto, Pere Ristol Debart, Montserrat Costa Rierola
Abstract: The present invention provides a biosafe and useful vector to transfer genetic material to CD14+ mononuclear cells (monocytes and monocyte-derived macrophages) in an efficient and specific manner. The embodiment of the invention makes use of the chimeric human adenovirus vectors 5 carrying the short fiber of enterotropic Ad40 to transfer genetic material to the target CD14+ mononuclear cells.
Type:
Application
Filed:
April 28, 2010
Publication date:
February 23, 2012
Applicants:
UNIVERSITAT AUTÒNOMA DE BARCELONA, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIÓ INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL, GRIFOLS, S.A.
Inventors:
Miquel Àngel Gassull Duro, Adolfo Rio Fernandez, Ester Fernandez Gimeno, Miguel Chillón Rodriguez
Abstract: A process for purifying and collecting albumin from plasma and plasma fractions involves diafiltration of an albumin-containing plasma fraction; stabilizing the resulting albumin fraction with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin fraction; and diafiltering the pasteurized fraction to remove, along other things, stabilizers. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.
Type:
Grant
Filed:
November 11, 2008
Date of Patent:
January 3, 2012
Assignee:
Grifols, S.A.
Inventors:
Juan Ignacio Jorquera Nieto, Pere Ristol Debart, Montserrat Costa Rierola
Abstract: The invention discloses a purified albumin solution of human origin with low prekallicrein activator (PKA) activity and stability over time characterized in that it has an antithrombin content equal to or greater than 0.03 mg/g of albumin, and a process for production thereof by the partial extraction of the antithrombin during fractionation of the human plasma.
Type:
Grant
Filed:
March 21, 2007
Date of Patent:
December 27, 2011
Assignee:
Grifols, S.A.
Inventors:
Juan Ignacio Jorquera Nieto, Nuria Hosta Mateu, Olga Santaeularia Lozano
Abstract: A method of treating a patient suffering from Haemophilia A and/or Von Willebrand's disease involves administering the patient a concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of up to 12 IU VWF:RCo/ml and a VWF/Factor VIII ratio of 0.4 or more, and nanofiltering that starting solution through a filter of pore size of about 35 nm or smaller. The resulting VWF retains high molecular weight multimers.
Type:
Application
Filed:
June 20, 2011
Publication date:
November 10, 2011
Applicant:
GRIFOLS, S.A.
Inventors:
Juan Ignacio JORQUERA NIETO, Pere RISTOL DEBART, Maria Mercedes FARO TOMAS
Abstract: A process for purifying and collecting albumin from plasma and plasma fractions involves diafiltration of an albumin-containing plasma fraction; stabilizing the resulting albumin fraction with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin fraction; and diafiltering the pasteurized fraction to remove, along other things, stabilizers. In one embodiment, the amino acid stabilizing agent is acetyl tryptophan. The resulting albumin has at least about 80% albumin binding capacity relative to natural plasma albumin, and is storage stable for about 30 months at 30° C.
Type:
Application
Filed:
February 15, 2011
Publication date:
June 9, 2011
Applicant:
GRIFOLS,S.A.
Inventors:
Juan Ignacio JORQUERA NIETO, Pere Ristol Debart, Montserrat Costa Rierola
Abstract: Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration. The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.
Type:
Grant
Filed:
December 9, 2009
Date of Patent:
April 26, 2011
Assignee:
Grifols, S.A.
Inventors:
Salvador Grancha Gamon, Anna Nardi Ricart, Josep Mariá Suñe Negre, Josep Ramón Tico Grau, Montserrat Miñarro Carmona
Abstract: System for the replenishment and filling of stores which comprises at least one full function device (FFD) capable of bidirectional wireless communication with at least one RFD and is capable of data processing, and at least one reduced function device (RFD) capable of bidirectional wireless communication, characterised in that said RFD comprises a push-button, an RF transceiver, an indicator device and a battery and also emits a restocking request signal to the FFD when said button is pressed.
Type:
Application
Filed:
October 13, 2010
Publication date:
April 14, 2011
Applicant:
GRIFOLS, S.A.
Inventors:
Manuel SANCHEZ MAULINI, Roberto Blanquer Torre
Abstract: The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.
Type:
Application
Filed:
October 29, 2010
Publication date:
February 24, 2011
Applicant:
GRIFOLS, S.A.
Inventors:
Daniel Martorell Pena, Ma del Carmen Traves Polo, Jordi Farre Leon, Josefina Castells Parera
Abstract: The present invention relates to mammalian cell culture media which comprise supernatant from some of the fractions of human plasma fractionation according to the Cohn method, more specifically, the supernatant of fractions I and II+III. When said supernatant is added as a culture medium supplement it provides various nutrients and factors for the effective maintenance and/or proliferation of the cultured mammalian cells. In addition, the present invention relates to the preparation process and use of said medium in the culture of mammalian cells.
Type:
Application
Filed:
July 2, 2010
Publication date:
February 3, 2011
Applicant:
GRIFOLS, S.A.
Inventors:
Juan Ignacio JORQUERA NIETO, Montserrat Costa Rierola, José María Diez Cervantes
Abstract: The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.
Type:
Application
Filed:
June 24, 2010
Publication date:
December 30, 2010
Applicant:
GRIFOLS, S.A.
Inventors:
Ana Garcia Quintana, José Alegre Martin
Abstract: The present invention relates to the use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders. In particular, the invention relates to methods of treating patients suffering from cognitive disorders, in which the mode of administration of the drug comprises the administration to the patient for a minimum of three successive times of a therapeutically effective amount of human therapeutic albumin by plasma exchange and/or intravenous perfusion, independently of the content of A? in the patient's blood.